Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Market Analysis and Insights: Global Viral Vectors Gene Therapy Market
The global Viral Vectors Gene Therapy market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Viral Vectors Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Viral Vectors Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Viral Vectors Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Viral Vectors Gene Therapy include Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics, Anges, Bluebird Bio, Jazz Pharmaceuticals and Dynavax Technologies, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Viral Vectors Gene Therapy market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Viral Vectors Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Viral Vectors Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vectors Gene Therapy revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Viral Vectors Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Viral Vectors Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics, Anges, Bluebird Bio, Jazz Pharmaceuticals and Dynavax Technologies, etc.
By Company
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
Segment by Type
Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors
Segment by Application
In Vivo
Ex Vivo
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Viral Vectors Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vectors Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vectors Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Retro Viral Vectors
1.2.3 Adeno-associated Virus Vectors
1.2.4 Other Viral Vectors
1.3 Market by Application
1.3.1 Global Viral Vectors Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 In Vivo
1.3.3 Ex Vivo
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vectors Gene Therapy Market Perspective (2018-2029)
2.2 Global Viral Vectors Gene Therapy Growth Trends by Region
2.2.1 Viral Vectors Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Viral Vectors Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Viral Vectors Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Viral Vectors Gene Therapy Market Dynamics
2.3.1 Viral Vectors Gene Therapy Industry Trends
2.3.2 Viral Vectors Gene Therapy Market Drivers
2.3.3 Viral Vectors Gene Therapy Market Challenges
2.3.4 Viral Vectors Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Viral Vectors Gene Therapy by Players
3.1.1 Global Viral Vectors Gene Therapy Revenue by Players (2018-2023)
3.1.2 Global Viral Vectors Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Viral Vectors Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Viral Vectors Gene Therapy, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Viral Vectors Gene Therapy Market Concentration Ratio
3.4.1 Global Viral Vectors Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vectors Gene Therapy Revenue in 2022
3.5 Global Key Players of Viral Vectors Gene Therapy Head office and Area Served
3.6 Global Key Players of Viral Vectors Gene Therapy, Product and Application
3.7 Global Key Players of Viral Vectors Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vectors Gene Therapy Breakdown Data by Type
4.1 Global Viral Vectors Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2024-2029)
5 Viral Vectors Gene Therapy Breakdown Data by Application
5.1 Global Viral Vectors Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Viral Vectors Gene Therapy Market Size (2018-2029)
6.2 North America Viral Vectors Gene Therapy Market Size by Type
6.2.1 North America Viral Vectors Gene Therapy Market Size by Type (2018-2023)
6.2.2 North America Viral Vectors Gene Therapy Market Size by Type (2024-2029)
6.2.3 North America Viral Vectors Gene Therapy Market Share by Type (2018-2029)
6.3 North America Viral Vectors Gene Therapy Market Size by Application
6.3.1 North America Viral Vectors Gene Therapy Market Size by Application (2018-2023)
6.3.2 North America Viral Vectors Gene Therapy Market Size by Application (2024-2029)
6.3.3 North America Viral Vectors Gene Therapy Market Share by Application (2018-2029)
6.4 North America Viral Vectors Gene Therapy Market Size by Country
6.4.1 North America Viral Vectors Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Viral Vectors Gene Therapy Market Size by Country (2018-2023)
6.4.3 North America Viral Vectors Gene Therapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Viral Vectors Gene Therapy Market Size (2018-2029)
7.2 Europe Viral Vectors Gene Therapy Market Size by Type
7.2.1 Europe Viral Vectors Gene Therapy Market Size by Type (2018-2023)
7.2.2 Europe Viral Vectors Gene Therapy Market Size by Type (2024-2029)
7.2.3 Europe Viral Vectors Gene Therapy Market Share by Type (2018-2029)
7.3 Europe Viral Vectors Gene Therapy Market Size by Application
7.3.1 Europe Viral Vectors Gene Therapy Market Size by Application (2018-2023)
7.3.2 Europe Viral Vectors Gene Therapy Market Size by Application (2024-2029)
7.3.3 Europe Viral Vectors Gene Therapy Market Share by Application (2018-2029)
7.4 Europe Viral Vectors Gene Therapy Market Size by Country
7.4.1 Europe Viral Vectors Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Viral Vectors Gene Therapy Market Size by Country (2018-2023)
7.4.3 Europe Viral Vectors Gene Therapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Viral Vectors Gene Therapy Market Size (2018-2029)
8.2 China Viral Vectors Gene Therapy Market Size by Type
8.2.1 China Viral Vectors Gene Therapy Market Size by Type (2018-2023)
8.2.2 China Viral Vectors Gene Therapy Market Size by Type (2024-2029)
8.2.3 China Viral Vectors Gene Therapy Market Share by Type (2018-2029)
8.3 China Viral Vectors Gene Therapy Market Size by Application
8.3.1 China Viral Vectors Gene Therapy Market Size by Application (2018-2023)
8.3.2 China Viral Vectors Gene Therapy Market Size by Application (2024-2029)
8.3.3 China Viral Vectors Gene Therapy Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Viral Vectors Gene Therapy Market Size (2018-2029)
9.2 Asia Viral Vectors Gene Therapy Market Size by Type
9.2.1 Asia Viral Vectors Gene Therapy Market Size by Type (2018-2023)
9.2.2 Asia Viral Vectors Gene Therapy Market Size by Type (2024-2029)
9.2.3 Asia Viral Vectors Gene Therapy Market Share by Type (2018-2029)
9.3 Asia Viral Vectors Gene Therapy Market Size by Application
9.3.1 Asia Viral Vectors Gene Therapy Market Size by Application (2018-2023)
9.3.2 Asia Viral Vectors Gene Therapy Market Size by Application (2024-2029)
9.3.3 Asia Viral Vectors Gene Therapy Market Share by Application (2018-2029)
9.4 Asia Viral Vectors Gene Therapy Market Size by Region
9.4.1 Asia Viral Vectors Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Viral Vectors Gene Therapy Market Size by Region (2018-2023)
9.4.3 Asia Viral Vectors Gene Therapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Viral Vectors Gene Therapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Viral Vectors Gene Therapy Introduction
11.1.4 Amgen Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.1.5 Amgen Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Viral Vectors Gene Therapy Introduction
11.2.4 Novartis Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.2.5 Novartis Recent Developments
11.3 Orchard Therapeutics
11.3.1 Orchard Therapeutics Company Details
11.3.2 Orchard Therapeutics Business Overview
11.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Introduction
11.3.4 Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.3.5 Orchard Therapeutics Recent Developments
11.4 Spark Therapeutics
11.4.1 Spark Therapeutics Company Details
11.4.2 Spark Therapeutics Business Overview
11.4.3 Spark Therapeutics Viral Vectors Gene Therapy Introduction
11.4.4 Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.4.5 Spark Therapeutics Recent Developments
11.5 Agc Biologics
11.5.1 Agc Biologics Company Details
11.5.2 Agc Biologics Business Overview
11.5.3 Agc Biologics Viral Vectors Gene Therapy Introduction
11.5.4 Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.5.5 Agc Biologics Recent Developments
11.6 Anges
11.6.1 Anges Company Details
11.6.2 Anges Business Overview
11.6.3 Anges Viral Vectors Gene Therapy Introduction
11.6.4 Anges Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.6.5 Anges Recent Developments
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Details
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Viral Vectors Gene Therapy Introduction
11.7.4 Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.7.5 Bluebird Bio Recent Developments
11.8 Jazz Pharmaceuticals
11.8.1 Jazz Pharmaceuticals Company Details
11.8.2 Jazz Pharmaceuticals Business Overview
11.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Introduction
11.8.4 Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.8.5 Jazz Pharmaceuticals Recent Developments
11.9 Dynavax Technologies
11.9.1 Dynavax Technologies Company Details
11.9.2 Dynavax Technologies Business Overview
11.9.3 Dynavax Technologies Viral Vectors Gene Therapy Introduction
11.9.4 Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.9.5 Dynavax Technologies Recent Developments
11.10 Biogen
11.10.1 Biogen Company Details
11.10.2 Biogen Business Overview
11.10.3 Biogen Viral Vectors Gene Therapy Introduction
11.10.4 Biogen Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.10.5 Biogen Recent Developments
11.11 Sarepta Therapeutics
11.11.1 Sarepta Therapeutics Company Details
11.11.2 Sarepta Therapeutics Business Overview
11.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Introduction
11.11.4 Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.11.5 Sarepta Therapeutics Recent Developments
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Details
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Viral Vectors Gene Therapy Introduction
11.12.4 Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2018-2023)
11.12.5 Gilead Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
*If Applicable.